MX2021013671A - Anticuerpos anti-sema3a y sus usos para tratar enfermedades oculares. - Google Patents

Anticuerpos anti-sema3a y sus usos para tratar enfermedades oculares.

Info

Publication number
MX2021013671A
MX2021013671A MX2021013671A MX2021013671A MX2021013671A MX 2021013671 A MX2021013671 A MX 2021013671A MX 2021013671 A MX2021013671 A MX 2021013671A MX 2021013671 A MX2021013671 A MX 2021013671A MX 2021013671 A MX2021013671 A MX 2021013671A
Authority
MX
Mexico
Prior art keywords
ocular diseases
treating eye
sema3a
antibodies
sema3a antibodies
Prior art date
Application number
MX2021013671A
Other languages
English (en)
Spanish (es)
Inventor
Leo Thomas
Sanjaya Singh
Rachel Rebecca Barrett
Rajkumar Ganesan
Priyanka Gupta
Sathyadevi Venkataramani
Kristin Laura Bovat
Fei Han
Dongmei Liu
Juergen Prestle
Helen Haixia Wu
Nina Zippel
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of MX2021013671A publication Critical patent/MX2021013671A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
MX2021013671A 2019-05-09 2020-05-08 Anticuerpos anti-sema3a y sus usos para tratar enfermedades oculares. MX2021013671A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19173454 2019-05-09
PCT/EP2020/062802 WO2020225400A1 (en) 2019-05-09 2020-05-08 Anti-sema3a antibodies and their uses for treating eye or ocular diseases

Publications (1)

Publication Number Publication Date
MX2021013671A true MX2021013671A (es) 2021-12-10

Family

ID=66476463

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021013671A MX2021013671A (es) 2019-05-09 2020-05-08 Anticuerpos anti-sema3a y sus usos para tratar enfermedades oculares.

Country Status (28)

Country Link
US (3) US11267880B2 (enExample)
EP (1) EP3966239A1 (enExample)
JP (2) JP7314310B2 (enExample)
KR (1) KR20220007128A (enExample)
CN (1) CN113795509A (enExample)
AR (1) AR122266A1 (enExample)
AU (1) AU2020267874A1 (enExample)
BR (1) BR112021019854A2 (enExample)
CA (1) CA3137377A1 (enExample)
CL (1) CL2021002795A1 (enExample)
CO (1) CO2021014768A2 (enExample)
CR (1) CR20210559A (enExample)
DO (1) DOP2021000226A (enExample)
EA (1) EA202193038A1 (enExample)
EC (1) ECSP21082527A (enExample)
IL (1) IL287758A (enExample)
JO (1) JOP20210300A1 (enExample)
MA (1) MA55872A (enExample)
MX (1) MX2021013671A (enExample)
MY (1) MY206253A (enExample)
NZ (1) NZ780763A (enExample)
PE (1) PE20220287A1 (enExample)
PH (1) PH12021552776A1 (enExample)
SA (1) SA521430793B1 (enExample)
SG (1) SG11202110842QA (enExample)
TW (1) TWI836069B (enExample)
UA (1) UA129953C2 (enExample)
WO (1) WO2020225400A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2021013671A (es) * 2019-05-09 2021-12-10 Boehringer Ingelheim Int Anticuerpos anti-sema3a y sus usos para tratar enfermedades oculares.
US20220127344A1 (en) * 2020-10-23 2022-04-28 Boehringer Ingelheim International Gmbh Anti-sema3a antibodies and their uses for treating a thrombotic disease of the retina
EP4314047A1 (en) 2021-03-30 2024-02-07 Bayer Aktiengesellschaft Anti-sema3a antibodies and uses thereof
CN116790610B (zh) * 2023-05-18 2024-09-20 四川大学 一种治疗骨科疾病的基因及以aav为载体的基因治疗药物

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4419446A (en) 1980-12-31 1983-12-06 The United States Of America As Represented By The Department Of Health And Human Services Recombinant DNA process utilizing a papilloma virus DNA as a vector
NZ201705A (en) 1981-08-31 1986-03-14 Genentech Inc Recombinant dna method for production of hepatitis b surface antigen in yeast
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4601978A (en) 1982-11-24 1986-07-22 The Regents Of The University Of California Mammalian metallothionein promoter system
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DD266710A3 (de) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4965199A (en) 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
DE68925971T2 (de) 1988-09-23 1996-09-05 Cetus Oncology Corp Zellenzuchtmedium für erhöhtes zellenwachstum, zur erhöhung der langlebigkeit und expression der produkte
FR2646437B1 (fr) 1989-04-28 1991-08-30 Transgene Sa Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
EP0940468A1 (en) 1991-06-14 1999-09-08 Genentech, Inc. Humanized antibody variable domain
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
DE69303494T2 (de) 1992-11-13 1997-01-16 Idec Pharma Corp Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
US6037454A (en) 1996-11-27 2000-03-14 Genentech, Inc. Humanized anti-CD11a antibodies
US5888809A (en) 1997-05-01 1999-03-30 Icos Corporation Hamster EF-1α transcriptional regulatory DNA
JP5888728B2 (ja) 2009-11-05 2016-03-22 国立大学法人大阪大学 自己免疫疾患又はアレルギー治療剤とそのスクリーニング方法
WO2013005603A1 (ja) * 2011-07-01 2013-01-10 公立大学法人横浜市立大学 結膜におけるアレルギー性炎症の予防及び／又は治療剤
ES2728854T3 (es) * 2013-02-06 2019-10-29 Univ Yokohama City Anticuerpo anti-semaforina 3A y tratamiento de enfermedad de Alzheimer y enfermedades inmunitarias inflamatorias usando el mismo
WO2014127479A1 (en) * 2013-02-21 2014-08-28 Rsem, Limited Partnership Inhibition of sema3a in the prevention and treatment of ocular hyperpermeability
SI3189074T1 (sl) 2014-09-05 2021-08-31 Rsem, Limited Partnership Sestavki in postopki za zdravljenje in preprečevanje vnetja
KR101854529B1 (ko) 2015-10-27 2018-05-04 (주) 팬젠 인간 및 마우스 Ｓｅｍａ３Ａ에 교차결합하는 항체 및 그의 용도
US10604571B2 (en) 2015-10-27 2020-03-31 Samsung Life Public Welfare Foundation Antibody to human and mouse SEMA3A and use thereof
AU2016346595B2 (en) 2015-10-27 2019-11-14 Pangen Biotech Inc. Antibody to be cross-linked to human and mouse Sema3A, and use thereof
MX2021013671A (es) * 2019-05-09 2021-12-10 Boehringer Ingelheim Int Anticuerpos anti-sema3a y sus usos para tratar enfermedades oculares.

Also Published As

Publication number Publication date
CA3137377A1 (en) 2020-11-12
PE20220287A1 (es) 2022-02-25
EA202193038A1 (ru) 2022-03-30
CN113795509A (zh) 2021-12-14
TW202108621A (zh) 2021-03-01
DOP2021000226A (enExample) 2021-12-15
JP7638332B2 (ja) 2025-03-03
CR20210559A (es) 2021-12-23
ECSP21082527A (es) 2021-12-30
US20240336674A1 (en) 2024-10-10
CL2021002795A1 (es) 2022-08-05
KR20220007128A (ko) 2022-01-18
JP2023130473A (ja) 2023-09-20
JP2022531698A (ja) 2022-07-08
TWI836069B (zh) 2024-03-21
US20200385446A1 (en) 2020-12-10
AU2020267874A1 (en) 2021-10-28
EP3966239A1 (en) 2022-03-16
US11267880B2 (en) 2022-03-08
US20220144929A1 (en) 2022-05-12
MA55872A (fr) 2022-03-16
SG11202110842QA (en) 2021-10-28
UA129953C2 (uk) 2025-09-24
BR112021019854A2 (pt) 2022-02-15
JOP20210300A1 (ar) 2023-01-30
WO2020225400A1 (en) 2020-11-12
MY206253A (en) 2024-12-05
CO2021014768A2 (es) 2021-11-19
NZ780763A (en) 2025-09-26
SA521430793B1 (ar) 2024-03-28
AR122266A1 (es) 2022-08-31
PH12021552776A1 (en) 2022-09-19
IL287758A (en) 2022-01-01
JP7314310B2 (ja) 2023-07-25

Similar Documents

Publication Publication Date Title
ECSP21082527A (es) Anticuerpos anti-sema3a y sus usos para tratar enfermedades oculares
CL2021000163A1 (es) Anticuerpos anti-htra1 y metodos de usos de los mismos. (divisional de solicitud 201801139)
CL2022000368A1 (es) Usos terapéuticos de anticuerpos anti-variable delta 1 de tcr
CL2020000483A1 (es) Nuevos usos de derivados de piperidinil–indol.
CO2018003852A2 (es) Proteínas de unión a antigeno que activan el receptor de leptina
CO2020009402A2 (es) Proteínas de fusión fc il-22 y métodos de uso
MX2018001532A (es) Anticuerpos anti-angptl8 y usos de estos.
MX2023004869A (es) Anticuerpos contra sars-cov-2 y usos de los mismos.
CL2023003694A1 (es) Anticuerpos anti-pcrv que se unen a pcrv, composiciones que comprenden anticuerpos anti-pcrv, métodos de uso
CO2023000557A2 (es) Anticuerpos y métodos para tratar enfermedades asociadas a claudina
BR112022005678A2 (pt) Métodos e composições para o tratamento da retinopatia diabética
DOP2024000117A (es) Anticuerpos anti-c3 y fragmentos de unión al antígeno de estos y sus usos para tratar enfermedades oftálmicas u oculares
EA202190576A1 (ru) Полиморфные соединения и их применение
CO2018004569A2 (es) Anticuerpos que se unen al receptor cannabinoide 1 (cb1) humano
MX2021006865A (es) Anticuerpos anti-alfa-sinucleina y usos de estos.
MX2021002652A (es) Uso de inhibidores de caseina-cinasa 1 para el tratamiento de enfermedades vasculares.
CR20220122A (es) Anticuerpos anti-nrp1a y sus usos para tratar enfermedades oculares
ECSP22020678A (es) Anticuerpos anti-nrp1a y sus usos para tratar enfermedades oculares
CL2023000955A1 (es) Anticuerpos anti-sema3a y sus usos para tratar una enfermedad trombótica de la retina
AR121317A2 (es) Anticuerpos anti-htra1 y métodos de uso de los mismos
AR122715A1 (es) Anticuerpos y métodos para tratar enfermedades asociadas a claudina
AR133072A2 (es) Anticuerpos aislados o fragmentos aislados de unión a antígeno de los mismos que se unen al receptor de leptina humana (lepr) y activan la señalización lepr
EA202091111A1 (ru) Модуляторы интегрированного стресса